Joseph Ciaffoni - Feb 10, 2023 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)

Signature
/s/ Colleen Tupper as Attorney-In-Fact For Joseph Ciaffoni
Stock symbol
COLL
Transactions as of
Feb 10, 2023
Transactions value $
-$2,901,700
Form type
4
Date filed
2/14/2023, 04:16 PM
Previous filing
Dec 27, 2022
Next filing
Jun 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COLL Common Stock Award $0 +118K +47.24% $0.00 366K Feb 10, 2023 Direct F1
transaction COLL Common Stock Award +138K +37.6% 504K Feb 10, 2023 Direct F2
transaction COLL Common Stock Tax liability -$1.18M -44.1K -8.76% $26.75 460K Feb 10, 2023 Direct F3
transaction COLL Common Stock Tax liability -$1.6M -59.7K -12.99% $26.75 400K Feb 10, 2023 Direct F4
transaction COLL Common Stock Options Exercise $179K +11.3K +2.81% $15.90 411K Feb 13, 2023 Direct
transaction COLL Common Stock Sale -$302K -11.3K -2.73% $26.88 400K Feb 13, 2023 Direct F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COLL Stock Option (Right to Purchase) Options Exercise $0 -11.3K -100% $0.00* 0 Feb 13, 2023 Common Stock 11.3K $15.90 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2024, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.
F2 Effective February 10, 2023, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 137,694 performance share units granted in the issuer's three prior fiscal years.
F3 Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
F4 Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units.
F5 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022.
F6 The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.485 to $27.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6).
F7 The option, initially representing a right to purchase a total of 90,00 shares, is fully vested and exercisable.